These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9179183)

  • 1. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue.
    Heerschap A; Jager GJ; van der Graaf M; Barentsz JO; de la Rosette JJ; Oosterhof GO; Ruijter ET; Ruijs SH
    Anticancer Res; 1997; 17(3A):1455-60. PubMed ID: 9179183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy.
    Kurhanewicz J; Vigneron DB; Nelson SJ; Hricak H; MacDonald JM; Konety B; Narayan P
    Urology; 1995 Mar; 45(3):459-66. PubMed ID: 7533458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.
    Kurhanewicz J; Vigneron DB; Hricak H; Narayan P; Carroll P; Nelson SJ
    Radiology; 1996 Mar; 198(3):795-805. PubMed ID: 8628874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
    Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR
    Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil.
    Kim JK; Kim DY; Lee YH; Sung NK; Chung DS; Kim OD; Kim KB
    Magn Reson Imaging; 1998 Dec; 16(10):1281-8. PubMed ID: 9858286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [1H magnetic resonance spectroscopy of the prostate].
    Mueller-Lisse UG; Scherr M
    Radiologe; 2003 Jun; 43(6):481-8. PubMed ID: 12827263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology.
    García-Segura JM; Sánchez-Chapado M; Ibarburen C; Viaño J; Angulo JC; González J; Rodríguez-Vallejo JM
    Magn Reson Imaging; 1999 Jun; 17(5):755-65. PubMed ID: 10372529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton MR spectroscopy of the prostate.
    Mueller-Lisse UG; Scherr MK
    Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton MR T2 maps correlate with the citrate concentration in the prostate.
    Liney GP; Lowry M; Turnbull LW; Manton DJ; Knowles AJ; Blackband SJ; Horsman A
    NMR Biomed; 1996 Apr; 9(2):59-64. PubMed ID: 8887369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic characterization of human prostate tissue with proton MR spectroscopy.
    Swindle P; McCredie S; Russell P; Himmelreich U; Khadra M; Lean C; Mountford C
    Radiology; 2003 Jul; 228(1):144-51. PubMed ID: 12832578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate.
    Kumar R; Kumar M; Jagannathan NR; Gupta NP; Hemal AK
    Urol Res; 2004 Feb; 32(1):36-40. PubMed ID: 14534764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Spectroscopic imaging (1H-2D-CSI) of the prostate: sequence optimization and correlation with histopathological results].
    Stanka M; Eltze E; Semjonow A; Sievert KD; Maier A; Pfleiderer B
    Rofo; 2000 Jul; 172(7):623-9. PubMed ID: 10962989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
    Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
    J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
    van Dorsten FA; van der Graaf M; Engelbrecht MR; van Leenders GJ; Verhofstad A; Rijpkema M; de la Rosette JJ; Barentsz JO; Heerschap A
    J Magn Reson Imaging; 2004 Aug; 20(2):279-87. PubMed ID: 15269954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis of localized prostate cancer.
    Saito K; Kaminaga T; Muto S; Ide H; Nishio K; Kamiyama Y; Okada H; Terado Y; Furui S; Horie S
    Anticancer Res; 2008; 28(3B):1899-904. PubMed ID: 18630478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
    Hom JJ; Coakley FV; Simko JP; Lu Y; Qayyum A; Westphalen AC; Schmitt LD; Carroll PR; Kurhanewicz J
    Radiology; 2007 Feb; 242(2):483-9. PubMed ID: 17179396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation.
    Wang XZ; Wang B; Gao ZQ; Liu JG; Liu ZQ; Niu QL; Sun ZK; Yuan YX
    Eur J Radiol; 2010 Feb; 73(2):345-51. PubMed ID: 19070978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility.
    Scheenen TW; Heijmink SW; Roell SA; Hulsbergen-Van de Kaa CA; Knipscheer BC; Witjes JA; Barentsz JO; Heerschap A
    Radiology; 2007 Nov; 245(2):507-16. PubMed ID: 17848681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy.
    Cornel EB; Smits GA; Oosterhof GO; Karthaus HF; Deburyne FM; Schalken JA; Heerschap A
    J Urol; 1993 Dec; 150(6):2019-24. PubMed ID: 7693985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.
    Hasumi M; Suzuki K; Oya N; Ito K; Kurokawa K; Fukabori Y; Yamanaka H
    Anticancer Res; 2002; 22(2B):1205-8. PubMed ID: 12168926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.